Purchases of property and equipment, including capitalized internal-use software, and proceeds from the issuance of debt for ...

Viant Technology Inc. (Nasdaq: DSP), a leader in AI-powered programmatic advertising, today reported financial results for its third quarter ended September 30, 2025.

Financial Assets ~~ Second Consecutive Quarter of Positive Operating Cash Flow ~~ Poised to Further Fulfill Mergers and ...

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with ...

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at ...

INLIGHT is currently ongoing at multiple trial sites, including in the US following clearance of an Investigational New Drug (IND) application. Wave has expanded Cohort 2, Cohort 3, and Cohort 4 (600 ...

Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period los ...

Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period ...

Third quarter 2025 net revenue was $118.8 million, up slightly compared to $118.6 million in the third quarter of 2024, fueled by the timing of Rejuvenate 2.0 shipments and the continued expansion of ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement ...

Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alo ...

Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions ...